Oct 08, 2019
VistaGen Therapeutics Announces Last Patient Completes Dosing in the ELEVATE Phase 2 Clinical Study of AV-101 for Major Depressive Disorder
Oct 03, 2019
Pacific Ketamine Institute Introduces SPRAVATO(TM) Treatment for Depression and Mental Disorders
Sep 16, 2019
Mindmed Acquires Opioid Addiction Drug Candidate Based on the Natural Psychedelic Ibogaine
Sep 11, 2019
Inhalation Anesthetics Market - Growth, Trends, and Forecast (2019 - 2024)
Aug 16, 2019
IV Ketamine Infusions Dramatically Improve the Quality of Life for Severe Migraine Patient
Aug 05, 2019
Neurotrope Announces Corporate Update and Reports Second Quarter 2019 Financial Results
Jul 29, 2019
Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression
Jun 06, 2019
Pacific Ketamine Institute Launches in Beverly Hills
May 31, 2019
Relmada Therapeutics Presents Development Program of REL1017 for Treatment of Depression at the 2019 American Society of Clinical Psychopharmacology Meeting
May 30, 2019
NeuroRx Reports Phase 2 Efficacy for NRX-101, a Breakthrough Therapy Targeting Suicidal Bipolar Depression
May 29, 2019
The global inhalation anesthesia market size is projected to reach USD 1.42 billion by 2015, at a lucrative CAGR of 3.5% over the forecast period
May 23, 2019
Pain Therapeutics Report, 2018-2019 & 2028 - Latest Concepts of Pathomechanisms of Pain as a Basis for Management and Development of New Pharmacotherapies
May 21, 2019
First Sublingual Ketamine Drug for Treatment of Acute Pain to be Evaluated in End-of-Phase 2 Meeting with FDA
Apr 18, 2019
Synergistic Therapeutics Obtains US Patent for Sublingual Ketamine Treatment for Depression
Apr 16, 2019
Relmada Therapeutics Announces Publication of REL1017 Phase 1 Studies Results
Apr 03, 2019
Gina DiGuglielmo Joins Relmada as Vice President and Head of Clinical Operations
Mar 14, 2019
New FDA-Approved Nasal Spray Anti-Depressant SPRAVATO(TM) Now Available in Bay Area at Palo Alto Mind Body
Mar 05, 2019
Houston based depression psychiatrist, Dr. Sandhya Prashad, M.D., tells how this new drug might save lives and cost less than expected
Mar 05, 2019
FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor's office or clinic
Feb 26, 2019
KNOW Bio Announces Creation of Digestive Health Therapeutics, Inc.